Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 3/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822000 | 0.80 | CA1 (0.42) | HSD11B1POLBGAASPRCNR1 | |
| SCHEMBL16825250 | 0.80 | POLB (0.38) | HSD11B1POLBGAASPRCNR1 | |
| SCHEMBL2104714 | 0.78 | TP53 (0.44) | HSD11B1 | |
| SCHEMBL18711984 | 0.75 | HSD11B1 (0.36) | HSD11B1POLBGAAJAK2JAK1 | |
| SCHEMBL28580229 | 0.74 | CNR1 (0.35) | HSD11B1POLBGAACNR1CNR2 | |
| SCHEMBL29905796 | 0.74 | ALDH1A1 (0.58) | GAAJAK2JAK1TYK2JAK3 | |
| SCHEMBL445149 | 0.69 | — | — | |
| SCHEMBL28578134 | 0.69 | ALDH1A1 (0.33) | HSD11B1POLBGAASPR | |
| Formaldehyde SCHEMBL28550791 | 0.67 | — | — | |
| SCHEMBL25279069 | 0.66 | TP53 (0.38) | GAACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | HSD11B1 2605/4885POLB 3763/4885GAA 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.